Comparison of Dermatology Life Quality Index Scores in Adults and Adolescents with Alopecia Areata.

IF 3.5 3区医学 Q1 DERMATOLOGY

Dermatology and Therapy Pub Date : 2025-06-01 Epub Date: 2025-04-24 DOI:10.1007/s13555-025-01417-y

Kent A Hanson, Sergio Vañó-Galván, Andrew Messenger, Helen Tran, Lynne Napatalung, Keith L Davis, Lizzi Esterberg, Ernest H Law

{"title":"Comparison of Dermatology Life Quality Index Scores in Adults and Adolescents with Alopecia Areata.","authors":"Kent A Hanson, Sergio Vañó-Galván, Andrew Messenger, Helen Tran, Lynne Napatalung, Keith L Davis, Lizzi Esterberg, Ernest H Law","doi":"10.1007/s13555-025-01417-y","DOIUrl":null,"url":null,"abstract":"Introduction: This study assessed Dermatology Life Quality Index (DLQI) scores of patients with alopecia areata (AA) and compared scores between adults and adolescents.Methods: This was a retrospective chart review in France, Germany, Spain, and the UK. Patients with ≥ 50% scalp hair loss (SHL) due to AA and a DLQI score recorded at their index date (first date of ≥ 50% SHL) were included. The DLQI (scale 0-30; higher scores indicate greater impact) assesses the impact of AA on health-related quality of life (QOL). Multivariable linear regression was used to examine the effect of age on DLQI score, adjusting for covariates. Modified Poisson regression analysis was used to estimate relative risks (RRs) between age groups and DLQI categories (none to moderate effect, very large effect, and extremely large effect), adjusting for covariates, including baseline Severity of Alopecia Tool (SALT) score.Results: Overall, 335 patients were included (249 adults, 86 adolescents). At index, adults had a higher mean (SD) SALT score than adolescents (63.7 [15.5] vs 60.4 [12.8]), whereas mean (SD) DLQI scores were higher in adolescents than adults (22.1 [5.3] vs 18.2 [7.5]). Most patients (84%) had DLQI scores indicating a very large or extremely large impact on their lives; this was more pronounced in adolescents than adults (98% vs 80%). In the multilinear model, adolescents had significantly higher DLQI scores than adults (β = 3.51; P < 0.001), indicating a 3.51-point increase in DLQI score associated with being an adolescent. The RR (95% CI) of a DLQI score indicating a very large effect (1.28 [1.07-1.53]) or extremely large effect (1.40 [1.21-1.61]) relative to no or moderate effect was significantly higher for adolescents vs adults.Conclusion: This study demonstrates that, at the time of experiencing ≥ 50% SHL due to AA, both adults and adolescents reported significant impacts on their QOL, with a higher impact on adolescents.","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"1543-1553"},"PeriodicalIF":3.5000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12092309/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-025-01417-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: This study assessed Dermatology Life Quality Index (DLQI) scores of patients with alopecia areata (AA) and compared scores between adults and adolescents.

Methods: This was a retrospective chart review in France, Germany, Spain, and the UK. Patients with ≥ 50% scalp hair loss (SHL) due to AA and a DLQI score recorded at their index date (first date of ≥ 50% SHL) were included. The DLQI (scale 0-30; higher scores indicate greater impact) assesses the impact of AA on health-related quality of life (QOL). Multivariable linear regression was used to examine the effect of age on DLQI score, adjusting for covariates. Modified Poisson regression analysis was used to estimate relative risks (RRs) between age groups and DLQI categories (none to moderate effect, very large effect, and extremely large effect), adjusting for covariates, including baseline Severity of Alopecia Tool (SALT) score.

Results: Overall, 335 patients were included (249 adults, 86 adolescents). At index, adults had a higher mean (SD) SALT score than adolescents (63.7 [15.5] vs 60.4 [12.8]), whereas mean (SD) DLQI scores were higher in adolescents than adults (22.1 [5.3] vs 18.2 [7.5]). Most patients (84%) had DLQI scores indicating a very large or extremely large impact on their lives; this was more pronounced in adolescents than adults (98% vs 80%). In the multilinear model, adolescents had significantly higher DLQI scores than adults (β = 3.51; P < 0.001), indicating a 3.51-point increase in DLQI score associated with being an adolescent. The RR (95% CI) of a DLQI score indicating a very large effect (1.28 [1.07-1.53]) or extremely large effect (1.40 [1.21-1.61]) relative to no or moderate effect was significantly higher for adolescents vs adults.

Conclusion: This study demonstrates that, at the time of experiencing ≥ 50% SHL due to AA, both adults and adolescents reported significant impacts on their QOL, with a higher impact on adolescents.

查看原文本刊更多论文

成人与青少年斑秃患者皮肤病学生活质量指数评分的比较。

本研究评估了斑秃（AA）患者的皮肤科生活质量指数（DLQI）评分，并比较了成人和青少年的评分。方法：回顾性分析法国、德国、西班牙和英国的病例。纳入AA导致头皮脱落(SHL)≥50%的患者，并在其指标日期（首次SHL≥50%的日期）记录DLQI评分。DLQI(范围0-30；得分越高表明影响越大)评估AA对健康相关生活质量（QOL）的影响。采用多变量线性回归检验年龄对DLQI评分的影响，调整协变量。修正泊松回归分析用于估计各年龄组和DLQI类别之间的相对风险（rr）（无至中等影响、非常大影响和极大影响），调整协变量，包括基线脱发严重程度工具（SALT）评分。结果：共纳入335例患者（249例成人，86例青少年）。在指数上，成人的平均（SD） SALT评分高于青少年（63.7[15.5]对60.4[12.8]），而青少年的平均（SD） DLQI评分高于成人（22.1[5.3]对18.2[7.5]）。大多数患者（84%）DLQI评分表明对他们的生活有非常大或极其大的影响；这在青少年中比在成年人中更为明显（98%对80%）。在多元线性模型中，青少年的DLQI得分显著高于成年人(β = 3.51；P结论：本研究表明，当AA导致的SHL≥50%时，成人和青少年的生活质量均受到显著影响，其中青少年的影响更大。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatology and Therapy Medicine-Dermatology

CiteScore

6.00

自引率

8.80%

发文量

187

审稿时长

6 weeks

期刊介绍： Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged. Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.